Welcome to our dedicated page for INTELGENX TECHS news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on INTELGENX TECHS stock.
IntelGenx Technologies Corp., based in Montreal, is dedicated to developing innovative proprietary technologies for enhanced drug delivery. The company's business strategy involves leveraging these technologies to enhance existing drug compounds with proven efficacy and safety. Through collaborations with strategic partners, IntelGenx reintroduces these compounds to the market as branded products with improved deliverability and efficacy. The company offers full-service pharmaceutical development, including formulation, clinical development, regulatory activities, manufacturing, and packaging. IntelGenx's experienced team works with both new chemical entities and established therapeutic active pharmaceutical ingredients, utilizing innovative drug delivery systems for a competitive edge and product extension opportunities.
Rhea-AI Summary
IntelGenx Technologies Corp. announces a Loan Agreement with atai Life Sciences AG, involving Additional Term Loans, Conversion Features, Warrants issuance, and related party transactions. atai advances up to US$2 million convertible into 10,810,810 Shares, aiming to beneficially own approximately 67% of the Company's issued and outstanding Shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary
IntelGenx Corp. announced a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock at $10.00 per share, aiming to raise $20,000,000. Holders will receive 8% yearly dividends and can convert each share into 20 common shares. The offering aims to support the pending U.S. commercial launch of RizaFilm® and strategic investments in the product pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Summary
IntelGenx Corp. announced a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock at $10.00 per share, aiming to raise a maximum of $20,000,000. The holders of the Series A Preferred Stock will receive cumulative dividends of $0.20 per share each quarter. The offering is intended to support the upcoming U.S. commercial launch of RizaFilm® and strategic investments in the company's product pipeline and services portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
Rhea-AI Summary
IntelGenx Corp. (IGXT) announced positive results from a proof-of-concept study evaluating the acceptance and ease of administration of its VetaFilm platform in dogs and cats. The study, conducted in collaboration with the University Prince Edward Island, showed high acceptance rates and ease of administration of VetaFilm FDOFs in both species. Dog owners and cat owners reported that administration of VetaFilm FDOFs was very easy or easy, with a majority identifying it as the preferred method of medication administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IntelGenx Corp. (IGX) announces development and license agreements with Covenant Animal Health, expanding its Animal Health business. Covenant Animal Health will fund development and manufacturing of a VetaFilm®-based drug, giving them exclusive rights to exploit the Product for non-human applications. IntelGenx will receive royalties on worldwide net sales of the Product and manufacture it for clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Summary
IntelGenx Technologies Corp. (IGX) closed a non-brokered private placement with atai Life Sciences AG for US$750,000. Shareholders approved the financing transactions. atai now has the ability to exercise a call option and purchase additional US Units. The participation of atai in the Subsequent atai Subscription and the grant of the Call Option constitute a 'related party transaction' within the meaning of MI 61-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
Rhea-AI Summary
IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors and the appointment of Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) shareholders approve financing transactions with atai Life Sciences AG, including the issuance of common stock and an increase in authorized shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
-
Rhea-AI Summary
IntelGenx Corp. (IGX) Announces Phase 2 MONTPARK Trial for Montelukast VersaFilm to Treat Parkinson’s Disease. The trial is approved by Swedish Medical Products Agency and aims to investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. Expected to begin recruiting patients in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) Urges Shareholders to Vote on Key Proposals at Upcoming Special Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of INTELGENX TECHS (IGXT)?
The current stock price of INTELGENX TECHS (IGXT) is $0.167 as of May 16, 2024.
What is the market cap of INTELGENX TECHS (IGXT)?
The market cap of INTELGENX TECHS (IGXT) is approximately 29.7M.
What is the primary focus of IntelGenx Technologies Corp.?
IntelGenx is dedicated to developing innovative proprietary technologies for enhanced drug delivery.
How does IntelGenx enhance existing drug compounds?
The company leverages its proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety.
What is IntelGenx's business strategy?
The company reintroduces enhanced drug compounds to the market as branded products with improved deliverability and efficacy through strategic partnerships.
What services does IntelGenx offer?
IntelGenx provides full-service pharmaceutical development, including formulation, clinical development, regulatory activities, manufacturing, and packaging.
What types of active pharmaceutical ingredients does IntelGenx work with?
IntelGenx works with both new chemical entities and established therapeutic active pharmaceutical ingredients.
What advantage do innovative drug delivery systems offer IntelGenx?
Innovative drug delivery systems provide significant competitive advantages and opportunities for product extension for IntelGenx.
Who can be contacted for investor relations at IntelGenx?
For investor relations, contact Stephen Kilmer at (647) 872-4849 or stephen@kilmerlucas.com.
Who is the President and CFO of IntelGenx Corp.?
Andre Godin is the President and CFO of IntelGenx Corp.
Where can copies of the SISP Order and procedures be obtained?
Copies of the SISP Order and procedures can be obtained from the website of the Monitor at www.ey.com/ca/intelgenx.
How can U.S. persons direct inquiries regarding IntelGenx?
U.S. persons should direct inquiries to Ernst & Young Corporate Finance (Canada) Inc. through Jatinder Wadhwa.
INTELGENX TECHS CORP